CAR-T Therapy Market Size, Share And Growth Analysis For 2024-2033

April 01, 2024 04:45 PM BST | By EIN Presswire
 CAR-T Therapy Market Size, Share And Growth Analysis For 2024-2033
Image source: EIN Presswire

LONDON, GREATER LONDON, UK, April 1, 2024 /EINPresswire.com/ -- The global market reports from The Business Research Company have been updated with the most recent market sizing data for 2024 and projections extended to 2033

The Business Research Company’s “CAR-T Therapy Global Market Report 2024 is a comprehensive source of information that covers every facet of the market. As per TBRC’s market forecast, the car-t therapy market size is predicted to reach $4.74 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%.

The growth in the car-t therapy market is due to the rising prevalence of cancer. North America region is expected to hold the largest car-t therapy market share. Major players in the car-t therapy market include Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd., Aeon Therapeutics, CARsgen Therapeutics, Daiichi Sankyo.

CAR-T Therapy Market Segments
• By Type: Monotherapy, Combination Therapy
• By Target Antigen: CD19, CD22, BCMA, Other Target Antigens
• By Application: Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Other Applications
• By Geography: The global car-t therapy market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Learn More On The Market By Requesting A Free Sample (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=6670&type=smp

The chimeric antigen receptor-T therapy is a type of immunotherapy in which T-cells are taken from the patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as the chimeric antigen receptor (CAR), attaches to a specific protein in a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs.

Read More On The CAR-T Therapy Global Market Report At:
https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report

The Table Of Content For The Market Report Include:
1. Executive Summary
2. CAR-T Therapy Market Characteristics
3. CAR-T Therapy Market Trends And Strategies
4. CAR-T Therapy Market – Macro Economic Scenario
5. CAR-T Therapy Market Size And Growth
……
27. CAR-T Therapy Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Market
29. CAR-T Therapy Market Future Outlook and Potential Analysis
30. Appendix

Browse Through More Similar Reports By The Business Research Company?

Stem Cell/Cord Blood Banking Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

Bioinformatics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/bioinformatics-global-market-report

Electrophysiology Devices And Equipment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/electrophysiology-devices-and-equipment-global-market-report

Contact Information
The Business Research Company: https://www.thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: [email protected]

Check out our:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
Twitter
LinkedIn


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next